

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1177949 CAPLUS Full-text
 DN 143:434728
 TI Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
 IN Shou, Yaping; Siu, Yin-Fai; Walker, George T.
 PA USA
 SO U.S. Pat. Appl. Publ., 26 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005244913	A1	20051103	US 2005-106239	20050414
	WO 2005113797	A2	20051201	WO 2005-US12948	20050414
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2004-563078P P 20040416

AB The invention discloses methods for determining the activity of Lp-PLA2 (PAF acetylhydrolase) in at least one sample from an animal. The invention also discloses methods for determining the inhibition of Lp-PLA2 activity in samples from animals that are administered an Lp-PLA2 inhibitor.


IT 304694-39-1

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity)

RN 304694-39-1 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

F

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:215748 CAPLUS Full-text

DN 139:78433

TI The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2

AU Blackie, Josie A.; Bloomer, Jackie C.; Brown, Murray J. B.; Cheng, Hung-Yuan; Hammond, Beverley; Hickey, Deirdre M. B.; Ife, Robert J.; Leach, Colin A.; Lewis, V. Ann; Macphee, Colin H.; Milliner, Kevin J.; Moores, Kitty E.; Pinto, Ivan L.; Smith, Stephen A.; Stansfield, Ian G.; Stanway, Steven J.; Taylor, Maxine A.; Theobald, Colin J.

CS Medicines Research Centre, GlaxoSmithKline, Stevenage, SG1 2NY, UK

SO Bioorganic & Medicinal Chemistry Letters (2003), 13(6), 1067-1070

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal

LA English

OS CASREACT 139:78433

AB Modification of the pyrimidone 5-substituent in clin. candidate SB-435495 has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A2 with sub-nanomolar potency. Cyclopentyl fused derivative 21, SB-480848, showed an enhanced in vitro and in vivo profile vs. SB-435495 and has been selected for progression to man.

IT 552857-42-8P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(design and structure activity of lipoprotein-associated phospholipase A2 inhibitor SB-480848)

RN 552857-42-8 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-(2-aminoethyl)-2-[[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

F

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:154252 CAPLUS Full-text
 DN 138:205073
 TI Preparation of 2,5-substituted 1-(aminocarbonylalkyl)-pyrimidin-4-ones
 with Lp-PLA2 inhibitory activity for the treatment of atherosclerosis
 IN Elliott, Richard Leonard; Leach, Colin Andrew; Smith, Stephen Allan
 PA Smithkline Beecham P.L.C., UK
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003015786	A1	20030227	WO 2002-EP9068	20020813
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2001-19793	A	20010814		
OS	MARPAT 138:205073				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1, R2 = (un)substituted (hetero)aryl; R3 = Het(alkyl) (wherein Het = (un)substituted 5-7 membered heterocyclyl, bonded directly through a ring carbon atom, comprising N atom and optionally O or S); R4 = (un)substituted (hetero)aryl; R5 = (un)substituted aryl; n = 1-4; X = O, S; Z = CR13R14 (R13, R14 = H, alkyl; or R13 and R14 together with the intervening carbon atom form cycloalkyl)] which are inhibitors of lipoprotein-associated phospholipase A2 (Lp-PLA2) and are of use in therapy, in particular for treating atherosclerosis, were prepared Thus, amidation of N-[1-(2-methoxyethyl)piperidin-4-yl]-4-(4-trifluoromethylphenyl)benzylamine with 1-(carboxymethyl)-2-(2,3-difluorobenzylthio)-5-[(1-methylpyrazol-4-yl)methyl]pyrimidin-4-one (prepns. given) in the presence of HATU and (iso-Pr)2NH in DMF afforded II. The compds. I described in the examples were tested for Lp-PLA2 inhibition and demonstrated IC50 values in the range 1 to 0.01 nM.

IT 500132-05-8P 500132-06-9P 500132-08-1P
 500132-09-2P 500132-13-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,5-substituted 1-(aminocarbonylalkyl)-pyrimidin-4-ones with Lp-PLA2 inhibitory activity for the treatment of atherosclerosis)

RN 500132-05-8 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidinyl]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-

[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 500132-06-9 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[(2,3-difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidiny]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 500132-05-8

CMF C40 H41 F5 N6 O3 S




CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 500132-08-1 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-N-(1-ethyl-4-piperidinyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 500132-09-2 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-N-(1-ethyl-4-piperidinyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 500132-08-1

CMF C39 H39 F5 N6 O2 S




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 500132-13-8 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F

RE.CNT 8


THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:641070 CAPLUS Full-text
 DN 138:280725
 TI The discovery of SB-435495: A potent, orally active inhibitor of
 lipoprotein-associated phospholipase A2 for evaluation in man
 AU Blackie, Josie A.; Bloomer, Jackie C.; Brown, Murray J. B.; Cheng,
 Hung-Yuan; Elliott, Richard L.; Hammond, Beverley; Hickey, Deirdre M. B.;
 Ife, Robert J.; Leach, Colin A.; Lewis, V. Ann; Macphee, Colin H.;
 Milliner, Kevin J.; Moores, Kitty E.; Pinto, Ivan L.; Smith, Stephen A.;
 Stansfield, Ian G.; Stanway, Steven J.; Taylor, Maxine A.; Theobald, Colin
 J.; Whittaker, Caroline M.
 CS GlaxoSmithKline, Medicines Research Centre, Stevenage, SG1 2NY, UK
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(18), 2603-2606
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB The introduction of a functionalized amido substituent into a series of 1-
 (biphenylmethylacetamido)-pyrimidones has given a series of inhibitors of
 recombinant lipoprotein-associated phospholipase A2 with sub-nanomolar potency
 and very encouraging developability properties. Diethylaminoethyl derivative,
 SB-435495, was selected for progression to man.
 IT **304694-18-6P 304694-31-3P 304694-39-1P, SB**
435495 304694-66-4P 304694-68-6P 304694-69-7P
503534-59-6P 503534-60-9P 503534-61-0P
503534-62-1P 503534-63-2P 503534-64-3P
503534-65-4P 503534-66-5P 503534-67-6P
503534-68-7P 503534-69-8P 503534-70-1P
503534-71-2P 503534-72-3P 503534-73-4P
503534-74-5P 503534-75-6P 503534-76-7P
503534-77-8P 503534-78-9P 503534-79-0P
503534-80-3P 503534-81-4P 503534-82-5P
503534-83-6P 503534-84-7P 503534-85-8P
503534-86-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (pyrimidone SB-435495 as a lipoprotein-associated phospholipase A2
 inhibitor)
 RN 304694-18-6 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-
 yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 304694-31-3 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 304694-39-1 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



F


RN 304694-66-4 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 304694-68-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


1
F

RN 304694-69-7 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[2-(dimethylamino)ethyl]-2-[[(4-

fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-
[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


f

RN 503534-59-6 CAPLUS
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
[[4-(4-fluorophenyl)methyl]thio]-N-(2-hydroxyethyl)-5-[(2-methoxy-5-
pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 503534-60-9 CAPLUS

CN Glycine, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[[2-[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo-1(4H)-pyrimidinyl]acetyl]- (9CI) (CA INDEX NAME)





RN 503534-61-0 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)-2-oxoethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 503534-62-1 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 503534-63-2 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-ethyl-2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 503534-64-3 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-(2-hydroxyethyl)-5-[(1-methyl-1H-pyrazol-
 4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 503534-65-4 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-(2-methoxyethyl)-5-[(1-methyl-1H-pyrazol-
 4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 503534-66-5 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(
 dimethylamino)-2-oxoethyl]-2-[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-
 1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F


RN 503534-67-6 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(ethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F

RN 503534-68-7 CAPLUS


CN 1(4H)-Pyrimidineacetamide, N-(2-aminoethyl)-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F


RN 503534-69-8 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[2-[bis(1-methylethyl)amino]ethyl]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F


RN 503534-70-1 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



F

RN 503534-71-2 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-
 N-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


F

RN 503534-72-3 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-N-[2-
 (4-morpholinyl)ethyl]-4-oxo- (9CI) (CA INDEX NAME)



F


RN 503534-73-4 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-[ethyl (2-hydroxyethyl) amino]ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F

RN 503534-74-5 CAPLUS


CN 1(4H)-Pyrimidineacetamide, N-[2-[bis(2-hydroxyethyl)amino]ethyl]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F


RN 503534-75-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[3-(dimethylamino)propyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F


RN 503534-76-7 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[3-(diethylamino)propyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F

RN 503534-77-8 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-
 N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


F

RN 503534-78-9 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-N-[3-
 (4-morpholinyl)propyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 503534-79-0 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-N-[3-(4-methyl-1-piperazinyl)propyl]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 503534-80-3 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, 2-[[(4-fluorophenyl)methyl]thio]-N-(2-hydroxyethyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




F

RN 503534-81-4 CAPLUS
 CN Glycine, N-[[2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1(4H)-pyrimidinyl]acetyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




F

RN 503534-82-5 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[2-(dimethylamino)-2-oxoethyl]-2-[[[4-(trifluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




F

RN 503534-83-6 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, 2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-N-[2-(4-morpholinyl)-2-oxoethyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




F

RN 503534-84-7 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[2-(ethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




F

RN 503534-85-8 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, 2-[[[4-(trifluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[2-(1-piperidiny)ethyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



f


RN 503534-86-9 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[3-(dimethylamino)propyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




f

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:900066 CAPLUS Full-text
 DN 136:256730
 TI Potent, orally active inhibitors of lipoprotein-associated phospholipase
 A2: 1-(biphenylmethylamidoalkyl)-pyrimidones
 AU Boyd, Helen F.; Fell, Stephen C. M.; Hickey, Deirdre M. B.; Ife, Robert
 J.; Leach, Colin A.; MacPhee, Colin H.; Milliner, Kevin J.; Pinto, Ivan
 L.; Rawlings, D. Anthony; Smith, Stephen A.; Stansfield, Ian G.; Stanway,
 Steven J.; Theobald, Colin J.; Whittaker, Caroline M.
 CS GlaxoSmithKline, Medicines Research Centre, Stevenage, SG1 2NY, UK
 SO Bioorganic & Medicinal Chemistry Letters (2001), Volume Date 2002, 12(1),
 51-55
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 136:256730
 GI




AB A series of 1-(biphenylmethylamidoalkyl)-pyrimidones has been designed as
 nanomolar inhibitors of recombinant lipoprotein-associated phospholipase A2
 with high potency in whole human plasma. Two compds. (I, R=1-methylpyrazol-4-
 yl or 5-(2-methoxypyrimidin-5-yl)) demonstrated excellent pharmacodynamic
 profiles which correlated well with their pharmacokinetic effects.
 IT **304694-18-6P 304694-66-4P**
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (1-(biphenylmethylamidoalkyl)-pyrimidones as inhibitors of
 lipoprotein-associated phospholipase A2)
 RN 304694-18-6 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-
 yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F

RN 304694-66-4 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT 304694-26-6P 304694-64-2P 405139-98-2P
 405139-99-3P 405140-00-3P 405140-01-4P

405140-02-5P 405140-03-6P 405140-04-7P
 405140-05-8P 405140-06-9P 405140-07-0P
 405140-08-1P 405140-09-2P 405140-10-5P
 405140-11-6P 405140-12-7P 405140-13-8P
 405140-14-9P 405140-15-0P 405140-16-1P
 405140-17-2P 405140-18-3P 405140-19-4P
 405140-20-7P 405140-21-8P 405140-22-9P
 405140-23-0P 405140-24-1P 405140-25-2P
 405140-26-3P 405140-27-4P 405140-28-5P
 405140-29-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(1-(biphenylmethylamidoalkyl)-pyrimidones as inhibitors of
 lipoprotein-associated phospholipase A2)


RN 304694-26-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-methyl-5-[[2-(4-morpholinyl)-5-
 pyrimidinyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 304694-64-2 CAPLUS


CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-
 [(1,2-dihydro-2-oxo-5-pyrimidinyl)methyl]-2-[[4-fluorophenyl)methyl]thio]-

N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 405139-98-2 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-4-ylmethyl)-2-[[4-(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 405139-99-3 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-4-ylmethyl)-2-[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 405140-00-3 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-3-ylmethyl)-2-[[4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 405140-01-4 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-2-ylmethyl)-2-[[4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 405140-02-5 CAPLUS


CN 1(4H)-Pyrimidineacetamide, N-([1,1'-biphenyl]-4-ylmethyl)-2-[[4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 405140-03-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F

RN 405140-04-7 CAPLUS
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-
(9CI) (CA INDEX NAME)


PAGE 1-A



F

RN 405140-05-8 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-bromo[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


F

RN 405140-06-9 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, 2-[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



F


RN 405140-07-0 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(3'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)



F

RN 405140-08-1 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(2'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-
 yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


F

RN 405140-09-2 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, 2-[[4-fluorophenyl)methyl]thio]-N-methyl-N-
 [(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-5-[(1-methyl-1H-pyrazol-4-
 yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 405140-10-5 CAPLUS
CN 1(4H)-Pyrimidineacetamide, 2-[[(4-fluorophenyl)methyl]thio]-N-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 405140-11-6 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-cyano[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




F

RN 405140-12-7 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, 2-[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-N-[[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-4-oxo- (9CI) (CA INDEX NAME)



F


RN 405140-13-8 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-
 methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-14-9 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-

Clc1ccc(cc1)-c2ccc(cc2)CNCC(=O)CN(C3=CC(=C(C=C3)C)C(=O)N4C=CC(=C4)C5=CC=CC=C5F)CC6=CC=CC=C6C

CN 1(4H)-Pyrimidineacetamide, 2-[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




CN 1(4H)-Pyrimidinebutanamide, N-([1,1'-biphenyl]-4-ylmethyl)-2-[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-
(9CI) (CA INDEX NAME)



RN 405140-17-2 CAPLUS

CN 1(4H)-Pyrimidinebutanamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


F

RN 405140-18-3 CAPLUS

CN 1(4H)-Pyrimidinebutanamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-

[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

1


RN 405140-19-4 CAPLUS
CN 1-(4H)-Pyrimidinebutanamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




RN 405140-20-7 CAPLUS

CN 1(4H)-Pyrimidinebutanamide, N-([1,1'-biphenyl]-4-ylmethyl)-2-[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI)
(CA INDEX NAME)




RN 405140-21-8 CAPLUS

CN 1(4H)-Pyrimidinebutanamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI)
(CA INDEX NAME)




RN 405140-22-9 CAPLUS

CN 1(4H)-Pyrimidinebutanamide, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-23-0 CAPLUS

CN 1(4H)-Pyrimidinebutanamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 405140-24-1 CAPLUS

CN 1(4H)-Pyrimidinebutanamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)





RN 405140-25-2 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[[2-(dimethylamino)-5-pyrimidinyl)methyl]-2-[[4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)





RN 405140-26-3 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-methyl-5-[[2-(4-methyl-1-piperazinyl)-5-
 pyrimidinyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)






RN 405140-27-4 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-[[2-(1-piperazinyl)-5-
 pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 405140-28-5 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-5-[[2-(trifluoromethyl)-5-
 pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 405140-29-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(1-ethyl-1,2-dihydro-2-oxo-5-pyrimidinyl)methyl]-2-[(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)





RE.CNT 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:790485 CAPLUS Full-text
 DN 133:335244
 TI Preparation of 1-acetamido-2-(arylkalkylthio)-4-pyrimidinones as
 lipoprotein associated phospholipase A2 inhibitors
 IN Fenwick, Ashley Edward; Hickey, Deirdre Mary Bernadette; Ife, Robert John;
 Leach, Colin Andrew; Pinto, Ivan Leo; Smith, Stephen Allan
 PA SmithKline Beecham PLC, UK
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066567	A1	20001109	WO 2000-EP3727	20000425
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2371671	AA	20001109	CA 2000-2371671	20000425
	EP 1175408	A1	20020130	EP 2000-920741	20000425
	EP 1175408	B1	20041201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200103216	T2	20020422	TR 2001-200103216	20000425
	BR 2000010220	A	20020514	BR 2000-10220	20000425
	JP 2002543190	T2	20021217	JP 2000-615598	20000425
	AU 766003	B2	20031009	AU 2000-41203	20000425
	NZ 515137	A	20031031	NZ 2000-515137	20000425
	EP 1479671	A1	20041124	EP 2004-77397	20000425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY				
	AT 283845	E	20041215	AT 2000-920741	20000425
	PT 1175408	T	20050429	PT 2000-920741	20000425
	ES 2233361	T3	20050616	ES 2000-920741	20000425
	NO 2001005329	A	20011031	NO 2001-5329	20011031
	ZA 2001008991	A	20021020	ZA 2001-8991	20011031
	US 6953803	B1	20051011	US 2002-30661	20020422
	HK 1044757	A1	20050708	HK 2002-104602	20020620
	US 2004167142	A1	20040826	US 2004-776876	20040211
PRAI	GB 1999-10048	A	19990501		
	GB 2000-2096	A	20000128		
	EP 2000-920741	A3	20000425		
	WO 2000-EP3727	W	20000425		
	US 2002-30661	A3	20020422		
OS	MARPAT 133:335244				
GI					



AB The title compds. (I) [wherein R1, R2, and R4 = independently (un)substituted (hetero)aryl; R3 = H or (un)substituted alkyl; R5 = (un)substituted aryl; n = 1-4, preferably 1 or 3; X = O or S; Z = CR13R14; R13 and R14 = independently H or alkyl; or CR13R14 = cycloalkyl] were prepared as inhibitors of the phospholipase A2 enzyme Lp-PLA2 for the treatment of atherosclerosis. For example, II was formed by amidation of 1-(carboxymethyl)-2-(4-fluorobenzylthio)-5-((1-methylpyrazol-4-yl)methyl)pyrimidin-4-one with N-methyl-4-(4-chlorophenyl)benzylamine (preparation for both starting materials given). I inhibited recombinant Lp-PLA2 enzyme activity with IC50 values in the range of 0.001 to 0.00005 μ M.

IT **304694-35-7P 304694-39-1P 304694-48-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 1-acetamido-2-(arylalkylthio)-4-pyrimidinone Lp-PLA2 inhibitors by amidation of 1-(carboxymethyl)-2-(arylalkylthio)-4-pyrimidinones with (hetero)arylalkylamines for the treatment of atherosclerosis)


RN 304694-35-7 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-31-3

CMF C37 H40 Cl F N6 O2 S




F

CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 304694-39-1 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F


RN 304694-48-2 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-(trifluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

F



IT 304694-18-6P 304694-20-0P 304694-24-4P
 304694-26-6P 304694-29-9P 304694-31-3P
 304694-32-4P 304694-33-5P 304694-36-8P
 304694-37-9P 304694-41-5P 304694-43-7P
 304694-45-9P 304694-52-8P 304694-53-9P
 304694-56-2P 304694-60-8P 304694-64-2P
 304694-68-6P 304694-69-7P 304694-71-1P
 304695-43-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-acetamido-2-(arylalkylthio)-4-pyrimidinone Lp-PLA2 inhibitors by amidation of 1-(carboxymethyl)-2-(arylalkylthio)-4-pyrimidinones with (hetero)arylalkylamines for the treatment of atherosclerosis)

RN 304694-18-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[(4-fluorophenyl)methyl]thio]-N-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

1
F


RN 304694-20-0 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-α-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



F



RN 304694-24-4 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




F

● HCl

RN 304694-26-6 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-
 [[(4-fluorophenyl)methyl]thio]-N-methyl-5-[[2-(4-morpholinyl)-5-
 pyrimidinyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 304694-29-9 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[2-(dimethylamino)ethyl]-2-[[(4-
 fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-
 [[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, monohydrochloride
 (9CI) (CA INDEX NAME)




F

● HCl

RN 304694-31-3 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)




PAGE 2-A

1
F

RN 304694-32-4 CAPLUS
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

1
F


● HCl

RN 304694-33-5 CAPLUS
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI)
(CA INDEX NAME)

CM 1

CRN 304694-31-3
CMF C37 H40 Cl F N6 O2 S

PAGE 1-A




PAGE 2-A

$\frac{1}{F}$

CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 304694-36-8 CAPLUS
CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 304694-31-3
CMF C37 H40 Cl F N6 O2 S

PAGE 1-A




PAGE 2-A

1
F

CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 304694-37-9 CAPLUS
CN Ethanesulfonic acid, 2-[[[(3 α ,5 β ,7 α ,12 α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-, compd. with N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1(4H)-pyrimidineacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-31-3
 CMF C37 H40 Cl F N6 O2 S

PAGE 1-A




PAGE 2-A

1
F

CM 2

CRN 81-24-3
 CMF C26 H45 N O7 S


Absolute stereochemistry.



RN 304694-41-5 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[(4-

fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-
[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, monohydrochloride
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


F

● HCl

RN 304694-43-7 CAPLUS
CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-39-1
CMF C38 H40 F4 N6 O2 S




F

CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 304694-45-9 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-(trifluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-39-1

CMF C38 H40 F4 N6 O2 S




F

CM 2



CRN 77-92-9

CMF C6 H8 O7



RN 304694-52-8 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-(trifluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl)methyl]-, monohydrochloride (9CI)
(CA INDEX NAME)





● HCl

RN 304694-53-9 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl)methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-48-2

CMF C37 H39 F4 N7 O2 S




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 304694-56-2 CAPLUS


CN 1(4H)-Pyrimidineacetamide, 2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[2-(1-piperidinyl)ethyl]-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl)methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-55-1

CMF C38 H39 F4 N7 O2 S

PAGE 1-A



PAGE 2-A


F

CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 304694-60-8 CAPLUS


CN 1(4H)-Pyrimidineacetamide, N-(2-aminoethyl)-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



F

● HCl


RN 304694-64-2 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-
 [(1,2-dihydro-2-oxo-5-pyrimidinyl)methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-
 N-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 304694-68-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[2-(dimethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

1
F


RN 304694-69-7 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[2-(dimethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



F

RN 304694-71-1 CAPLUS
 CN Glycine, N-[[2-[[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1(4H)-pyrimidinyl]acetyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, sodium salt (9CI) (CA INDEX NAME)



F


● Na

RN 304695-43-0 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 304694-39-1
 CMF C38 H40 F4 N6 O2 S

PAGE 1-A




PAGE 2-A

F

CM 2

CRN 104-15-4
 CMF C7 H8 O3 S




IT **304694-59-5 304694-66-4**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1-acetamido-2-(arylalkylthio)-4-pyrimidinone Lp-PLA2 inhibitors by amidation of 1-(carboxymethyl)-2-(arylalkylthio)-4-pyrimidinones with (hetero)arylalkylamines for the treatment of atherosclerosis)

RN 304694-59-5 CAPLUS
 CN Glycine, N-[[2-[[[4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-

yl)methyl]-4-oxo-1(4H)-pyrimidinyl]acetyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

F

RN 304694-66-4 CAPLUS

CN 1(4H)-Pyrimidineacetamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(2-methoxy-5-pyrimidinyl)methyl]-N-methyl-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:325924 CAPLUS Full-text

DN 130:352278

TI Preparation of pyrimidinone derivatives as Lp-PLA2 inhibitors

IN Hickey, Deirdre Mary Bernadette; Ife, Robert John; Leach, Colin Andrew; Pinto, Ivan Leo; Porter, Roderick Alan; Smith, Stephen Allan

PA Smithkline Beecham PLC, UK

SO PCT Int. Appl., 210 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9924420	A1	19990520	WO 1998-EP6988	19981023
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2309177	AA	19990520	CA 1998-2309177	19981023
	AU 9911575	A1	19990531	AU 1999-11575	19981023
	EP 1028955	A1	20000823	EP 1998-954482	19981023
	EP 1028955	B1	20030716		
	R:	BE, CH, DE, ES, FR, GB, IT, LI, NL, SI			
	JP 2001522844	T2	20011120	JP 2000-520434	19981023
	ES 2203988	T3	20040416	ES 1998-954482	19981023
	ZA 9810112	A	20000505	ZA 1998-10112	19981105
	US 6417192	B1	20020709	US 2000-530713	20000628
	US 2002120139	A1	20020829	US 2002-115452	20020402
PRAI	GB 1997-23352	A	19971106		
	GB 1997-23358	A	19971106		
	WO 1998-EP6988	W	19981023		
	US 2000-530713	A3	20000628		
OS	MARPAT 130:352278				
GI					



AB The title compds. I [Z is a bond and R1 is halo, or Z is CR3R4 wherein R3 and R4 are each hydrogen, alkyl, or CR3R4 = cycloalkyl ring; R1 is aryl or heteroaryl group optionally substituted by 1 - 4 substituents; X = O, S; Y is AlA2A3 in which A1 and A3 each represent a bond or alkylene, and A2 represents a bond or O, S, etc.; a proviso is given; R2 is aryl or heteroaryl group optionally substituted by 1 - 4 substituents; W is a bond and R7 is hydrogen; or W is SO2 or a bond; R7 is R1 or hydrocarbonyl group (further detail on said


hydrocarbonyl group is given)] are prepared I are useful in the treatment of atherosclerosis (no data). For example, pyrimidinone derivative II was prepared. Compds. of this invention were found to have IC₅₀ values in the range 0.0001 to 60 μ M in the test for lipoprotein-associated phospholipase A₂ (Lp-PLA₂) inhibition.

IT 224774-36-1P 224774-37-2P 224774-60-1P
224774-61-2P 224774-65-6P 224774-97-4P
224774-98-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinone derivs. as Lp-PLA₂ inhibitors)


RN 224774-36-1 CAPLUS

CN 1(4H)-Pyrimidinehexanamide, 2-[[[(3,4-difluorophenyl)methyl]thio]-4-oxo-N-(2-phenylethyl)-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-37-2 CAPLUS

CN 1(4H)-Pyrimidinehexanamide, 2-[[[(3,4-difluorophenyl)methyl]thio]-N-methyl-4-oxo-N-(2-phenylethyl)-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-60-1 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-N-(2-phenylethyl)-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-61-2 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4-oxo-N-[2-(4-pentylphenyl)ethyl]-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-65-6 CAPLUS

CN 1(4H)-Pyrimidineacetamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-N-methyl-4-oxo-N-(2-phenylethyl)-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 224774-97-4 CAPLUS

CN Benzoic acid, 4-[[[2-[[[4-(4-fluorophenyl)methyl]thio]-4-oxo-5-(5-pyrimidinylmethyl)-1(4H)-pyrimidinyl]acetyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 224774-98-5 CAPLUS


CN 1(4H)-Pyrimidineacetamide, 2-[[[4-(4-fluorophenyl)methyl]thio]-4-oxo-N-(phenylmethyl)-5-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2; d his; log y
 L2 HAS NO ANSWERS
 L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 14:50:29 ON 21 APR 2006)

FILE 'REGISTRY' ENTERED AT 14:50:42 ON 21 APR 2006

L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 2 S L2
 L4 101 S L2 FUL

FILE 'CAPLUS' ENTERED AT 14:51:21 ON 21 APR 2006

L5 7 S L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	36.23	203.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.25	-5.25

STN INTERNATIONAL LOGOFF AT 14:52:09 ON 21 APR 2006